Arcturus Therapeutics (NASDAQ:ARCT) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16, FiscalAI reports. Arcturus Therapeutics had a negative return on equity of 44.42% and a negative net margin of 317.62%.The firm had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• ARCT-810 completed Phase II enrollment and dosing in OTC deficiency, with U.S. and European data expected in Q3 2026 alongside FDA-requested supplementary data and an update on the regulatory path for adult and pediatric development.
• ARCT-032’s Phase II cystic fibrosis study remains on schedule, supported by expanded enrollment in Israel and Turkey; Arcturus expects to decide whether to advance to Phase III in Q4 2026, which would trigger substantial manufacturing and development support from Thermo Fisher.
• Arcturus regained global rights to KOSTAIVE and its broader self-amplifying mRNA vaccine portfolio after ending the CSL Seqirus collaboration. The settlement included a $12 million cash payment and release from approximately $16 million in liabilities, while returning strategic control that could enable commercialization and new partnerships.
• Revenue fell sharply to $3 million in Q2 2026 from $28.3 million a year earlier as the CSL collaboration wound down, while cash declined to $191.5 million from $230.8 million at year-end 2025.
• Management said the company has more than two and a half years of cash runway through year-end 2028, but it will need to balance rare-disease clinical spending with efforts to commercialize or partner the returned vaccine assets.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock traded up $1.33 during trading hours on Friday, hitting $7.41. The stock had a trading volume of 1,461,125 shares, compared to its average volume of 442,082. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17. The stock has a market capitalization of $210.59 million, a price-to-earnings ratio of -2.24 and a beta of 2.39. The stock’s fifty day moving average is $6.77 and its two-hundred day moving average is $7.38.

Institutional Trading of Arcturus Therapeutics

Large investors have recently modified their holdings of the business. ARK Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 39.4% in the fourth quarter. ARK Investment Management LLC now owns 2,611,099 shares of the biotechnology company’s stock valued at $16,006,000 after acquiring an additional 738,378 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Arcturus Therapeutics by 1,371.4% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after purchasing an additional 514,652 shares in the last quarter. Millennium Management LLC purchased a new stake in Arcturus Therapeutics during the 1st quarter worth about $4,892,000. Bank of America Corp DE raised its stake in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Arcturus Therapeutics by 170.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,227 shares of the biotechnology company’s stock valued at $2,398,000 after purchasing an additional 246,499 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ARCT has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. Wall Street Zen downgraded shares of Arcturus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $24.25.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.